Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Thomas R. Yeager is active.

Publication


Featured researches published by Thomas R. Yeager.


Oncogene | 2002

Alternative lengthening of telomeres in mammalian cells.

Jeremy D. Henson; Axel A. Neumann; Thomas R. Yeager; Roger R. Reddel

Some immortalized mammalian cell lines and tumors maintain or increase the overall length of their telomeres in the absence of telomerase activity by one or more mechanisms referred to as alternative lengthening of telomeres (ALT). Characteristics of human ALT cells include great heterogeneity of telomere size (ranging from undetectable to abnormally long) within individual cells, and ALT-associated PML bodies (APBs) that contain extrachromosomal telomeric DNA, telomere-specific binding proteins, and proteins involved in DNA recombination and replication. Activation of ALT during immortalization involves recessive mutations in genes that are as yet unidentified. Repressors of ALT activity are present in normal cells and some telomerase-positive cells. Telomere length dynamics in ALT cells suggest a recombinational mechanism. Inter-telomeric copying occurs, consistent with a mechanism in which single-stranded DNA at one telomere terminus invades another telomere and uses it as a copy template resulting in net increase in telomeric sequence. It is possible that t-loops, linear and/or circular extrachromosomal telomeric DNA, and the proteins found in APBs, may be involved in the mechanism. ALT and telomerase activity can co-exist within cultured cells, and within tumors. The existence of ALT adds some complexity to proposed uses of telomere-related parameters in cancer diagnosis and prognosis, and poses challenges for the design of anticancer therapeutics designed to inhibit telomere maintenance.


Molecular and Cellular Biology | 2001

Coexistence of Alternative Lengthening of Telomeres and Telomerase in hTERT-Transfected GM847 Cells

Kilian Perrem; Lorel M. Colgin; Axel A. Neumann; Thomas R. Yeager; Roger R. Reddel

ABSTRACT It has been shown previously that some immortalized human cells maintain their telomeres in the absence of significant levels of telomerase activity by a mechanism referred to as alternative lengthening of telomeres (ALT). Cells utilizing ALT have telomeres of very heterogeneous length, ranging from very short to very long. Here we report the effect of telomerase expression in the ALT cell line GM847. Expression of exogenous hTERT in GM847 (GM847/hTERT) cells resulted in lengthening of the shortest telomeres; this is the first evidence that expression of hTERT in ALT cells can induce telomerase that is active at the telomere. However, rapid fluctuation in telomere length still occurred in the GM847/hTERT cells after more than 100 population doublings. Very long telomeres and ALT-associated promyelocytic leukemia (PML) bodies continued to be generated, indicating that telomerase activity induced by exogenous hTERT did not abolish the ALT mechanism. In contrast, when the GM847 cell line was fused with two different telomerase-positive tumor cell lines, the ALT phenotype was repressed in each case. These hybrid cells were telomerase positive, and the telomeres decreased in length, very rapidly at first and then at the rate seen in telomerase-negative normal cells. Additionally, ALT-associated PML bodies disappeared. After the telomeres had shortened sufficiently, they were maintained at a stable length by telomerase. Together these data indicate that the telomerase-positive cells contain a factor that represses the ALT mechanism but that this factor is unlikely to be telomerase. Further, the transfection data indicate that ALT and telomerase can coexist in the same cells.


Current Opinion in Biotechnology | 1999

Constructing immortalized human cell lines.

Thomas R. Yeager; Roger R. Reddel

Obtaining an abundant supply of human cells with specific differentiated properties is a key issue in many research studies and biotechnology applications. Recent advances in this area include the finding that forced expression of the enzyme telomerase can greatly increase the proliferative potential of at least some types of human cells, and also the development of methods for culturing human stem cells.


Lung Cancer | 2011

Telomerase activity in pleural malignant mesotheliomas

Amy Y.M. Au; Torben Hackl; Thomas R. Yeager; Scott B. Cohen; Harvey I. Pass; Curtis C. Harris; Roger R. Reddel

New treatments are needed for malignant pleural mesothelioma (MPM), which currently has a poor prognosis. Cellular immortalisation, one of the hallmarks of cancer, depends on the activity of a telomere length maintenance mechanism (TMM) - either telomerase or alternative lengthening of telomeres (ALT). The TMMs are widely regarded as potential targets for cancer therapies and telomerase inhibitors have entered clinical trials. The aim of this study was to determine what proportion of MPMs use ALT and/or telomerase. Forty-three MPMs from 42 patients were examined for telomerase and ALT activity. Telomerase activity was detected by immunoaffinity purification followed by the telomere repeat amplification protocol (TRAP), and ALT activity was determined by the C-circle assay and by assessing telomere lengths using terminal restriction fragment analyses. We found that 43 of 43 MPMs were telomerase-positive[+] and ALT-negative[-]. Therefore, to investigate whether pleural mesothelial cells are unusually susceptible to activation of telomerase, we examined activation of the TMMs in an in vitro model of cellular immortalisation, in which normal pleural mesothelial cells were transduced with simian virus 40 (SV40) oncogenes. We found that normal mesothelial cells were TMM-negative, and that expression of the SV40 oncogenes did not directly activate telomerase or ALT. Immortalisation, which in this experimental system results from additional genetic changes that have not yet been identified, was accompanied by activation of either TMM. Therefore, pleural mesothelial cells are capable of activating either TMM in vitro, and the observation that 100% of MPMs were telomerase[+] suggests that there are factors in vivo that select for telomerase activity during oncogenesis of this tumour type. We conclude that MPM is a tumour that could be considered for anti-telomerase therapy.


Archive | 1999

A Statistical Analysis of Cancer Genome Variation

Michael A. Newton; Thomas R. Yeager; Catherine A. Reznikoff

We consider separating signal and noise in data measuring genetic abnormalities of cancer tumor cells. The linked hot-cold model is introduced and t to data from a comparative genomic hybridization study of bladder cancer. We analyze these data and report details of the calculation summarized in Yeager et al. 1998. The model-generating framework developed in Newton et al. 1998 is used to motivate the linked hot-cold model.


Cancer Research | 1999

Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body.

Thomas R. Yeager; Axel A. Neumann; Anna Englezou; Lily I. Huschtscha; Jane R. Noble; Roger R. Reddel


Proceedings of the National Academy of Sciences of the United States of America | 1997

Telomerase activity: A biomarker of cell proliferation, not malignant transformation

Cassandra D. Belair; Thomas R. Yeager; Patricia Lopez; Catherine A. Reznikoff


Clinical Cancer Research | 2005

A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas

Jeremy D. Henson; Jonathan Hannay; Stanley W. McCarthy; Janice A. Royds; Thomas R. Yeager; Robert A. Robinson; Stephen Wharton; David Jellinek; Susan Arbuckle; Jinyoung Yoo; Bruce G. Robinson; Diana L. Learoyd; Paul Stalley; S. Fiona Bonar; Dihua Yu; Raphael E. Pollock; Roger R. Reddel


Cancer Research | 1996

Elevated p16 at Senescence and Loss of p16 at Immortalization in Human Papillomavirus 16 E6, but not E7, Transformed Human Uroepithelial Cells

Catherine A. Reznikoff; Thomas R. Yeager; Cassandra D. Belair; Elena Savelieva; Jairaj A. Puthenveettil; Walter M. Stadler


Cancer Research | 1999

p16/pRb Pathway Alterations Are Required for Bypassing Senescence in Human Prostate Epithelial Cells

David F. Jarrard; Somdatta Sarkar; Yan Shi; Thomas R. Yeager; Gregg Magrane; Hidefumi Kinoshita; Nadine Nassif; Lorraine F. Meisner; Michael A. Newton; Frederic M. Waldman; Catherine A. Reznikoff

Collaboration


Dive into the Thomas R. Yeager's collaboration.

Top Co-Authors

Avatar

Roger R. Reddel

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Catherine A. Reznikoff

University of Wisconsin-Madison

View shared research outputs
Top Co-Authors

Avatar

Michael A. Newton

University of Wisconsin-Madison

View shared research outputs
Top Co-Authors

Avatar

Axel A. Neumann

Children's Medical Research Institute

View shared research outputs
Top Co-Authors

Avatar

Cassandra D. Belair

University of Wisconsin-Madison

View shared research outputs
Top Co-Authors

Avatar

David F. Jarrard

University of Wisconsin-Madison

View shared research outputs
Top Co-Authors

Avatar

Lorraine F. Meisner

University of Wisconsin-Madison

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Gregg Magrane

University of California

View shared research outputs
Researchain Logo
Decentralizing Knowledge